GH
What one share of Guardant Health holds
Services – Medical Laboratories
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics.
Guardant Health’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $9.14 |
|---|---|
| Profit | −$3.50 |
| Capex (buildings and equipment) | $0.43 |
| Free cash flow | −$1.86 |
| Cash and investments | $7.88 |
| Debt | $11.25 |
| Book value | −$1.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.93 | −$3.53 | $0.14 | −$2.95 | — | $6.11 |
| 2017 | $3.96 | −$7.07 | $0.53 | −$6.27 | — | $25.94 |
| 2018 | $2.98 | −$2.80 | $0.66 | −$3.04 | — | — |
| 2019 | $2.37 | −$0.83 | $0.21 | −$0.73 | — | $8.47 |
| 2020 | $2.94 | −$2.60 | $0.37 | −$1.44 | — | $12.96 |
| 2021 | $3.69 | −$4.00 | $0.74 | −$2.80 | — | $6.34 |
| 2022 | $4.40 | −$6.41 | $0.76 | −$3.79 | — | $0.59 |
| 2023 | $5.04 | −$4.28 | $0.18 | −$3.08 | — | $1.30 |
| 2024 | $6.02 | −$3.56 | $0.29 | −$2.24 | — | −$1.13 |
| 2025 | $7.83 | −$3.32 | $0.39 | −$1.86 | — | −$0.76 |